BioMed Realty Trust Inc. is a real estate investment trust (REIT) focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry.   

Since first representing Hybritech in 1981, the Burnham Life Sciences Group has built a business devoted exclusively to supporting and promoting the life science community.   

After years of growing concern over poor patent quality and out-of-control patent litigation, a bill with the most sweeping reforms in 50 years was introduced in Congress this summer.   

Time is money. That pragmatic advice offered by Benjamin Franklin in 1748 is one of the undisputed truisms of today's commercial real estate industry.   

The city of Poway invites life-science businesses to evaluate our community as a potential site for their next expansion or relocation opportunity.   

Knobbe Martens Olson & Bear, the largest intellectual property specialty law firm in the Western United States, has consistently been recognized by trade groups and publications as one of the leading IP law firms in the region, the country and the world.   

Gemini Science is a wholly-owned U.S. subsidiary of Kirin Pharmaceuticals, located in San Diego and is Kirin's sole agent in the United States for facilitating Kirin's pharmaceutical business development efforts.   

The Sidney Kimmel Cancer Center (SKCC) announced recently that $24.5 million in bond financing has been obtained through the auspices of San Diego County and Bank of America to fund the construction of a 79,000-square-foot research center.   

Today's first time biotechnology entrepreneurs are finding their fund raising experience dramatically different than that of their predecessors.   

Most of us have known someone stricken by cancer. Chemotherapy may seem like the only viable treatment option, but doctors at Kaiser Foundation Hospital, UCSD Medical Center and Sharp Memorial Hospital in San Diego and other hospitals around the country, are testing a new way to fight non-Hodgkin's lymphoma (NHL).   

Federal legislation (H.R. 2795, introduced June 8) is pending that, if passed, will make the most sweeping reforms to the U.S. patent system since 1952.   

Where the local biotech real estate market is concerned, year-to-date 2005 leasing activity has been healthy, evidenced by a diminishing number of opportunities for space under 20,000 square feet.   

The Centient Biotech Investor, a newsletter for investors in public and private biotechnology companies, has announced its Centient Top 10 Biotech list, identifying the ten companies it believes will outperform the biotechnology sector as a whole over the next twelve months.   

A bank that will create and supply new lines of embryonic stem cells for scientists around the world opened in Seoul on Wednesday as part of a global partnership in the contentious field.   

A day after it reported losing $16.1 million in the third quarter, San Diego-based Arena Pharmaceuticals Inc. (Nasdaq: ARNA, News) on Tuesday announced  data from its positive Phase 2a clinical trial studying APD356 in 352 obese patients.   

La Jolla Pharmaceutical Co. (Nasdaq: LJPC, News) on Tuesday provided a summary of the status of the company's development program for Riquent, its drug candidate for lupus renal disease.    

Roche AG says it will build a U.S. plant to make more of its anti-bird flu drug Tamiflu, but that promise failed to tamp growing international pressure on the Swiss drug giant to ease its monopoly grip on the drug.   

San Diego attorneys Eric Kremer and Carmela Dunn Nicholas of Pillsbury Winthrop Shaw Pittman LLP advised Biosite Inc. (Nasdaq: BSTE) in its $28.2 million acquisition of approximately 26 usable acres at the Fenton Technology Park in the Miramar area of San Diego. The negotiation of the purchase documentation and the title due diligence along with the negotiation and documentation of the design and construction contracts were also completed by Pillsbury, working closely with Biosite's in-house facilities, finance and legal departments.   

An Idaho postal worker who suffered a heart attack had a buildup of plaque in his arteries that was not caused by the since-withdrawn painkiller Vioxx, a doctor testified Tuesday for the drug's maker in a product liability trial.   

TRENTON, N.J. (AP) - Johnson & Johnson's chief financial officer on Tuesday said the company is considering alternatives to its planned acquisition of troubled heart device maker Guidant Corp. as the health care company posted a 12 percent jump in third-quarter profit amid strong overseas sales.   

DUBLIN, Ireland (AP) - The two pharmaceutical companies who make the withdrawn drug Tysabri said Monday they had found no new cases of a rare brain disease among nearly 1,500 people who took the suspended drug to treat rheumatoid arthritis and Crohn's disease.   

Carlsbad-based Invitrogen Corp. (Nasdaq: IVGN, News) , a maker of genomics research equipment, said Thursday that an appeals court ruled in its favor in a patent infringement case brought against Stratagene Inc. (Nasdaq: STGN, News)   

Pfizer Inc. won a significant victory on Wednesday when a British judge upheld a key patent covering its blockbuster cholesterol drug Lipitor in the United Kingdom but the medication still faces a similar yet more important case in the United States.   

Eisai Co. Ltd. and TorreyPines Therapeutics Inc. jointly announced Tuesday the signing of a new research agreement that focuses on the discovery of genes responsible for late onset Alzheimer's disease.    

San Diego-based Biosite Inc. (Nasdaq: BSTE, News) announced Friday that it has increased the share reserve for its 2002 Nonqualified Stock Incentive Plan by 400,000 shares. The company also modified the plan to allow for the grant of inducement stock awards to officers in accordance with applicable Nasdaq rules.   

Reinforcing the strong performance in the capital markets in the third quarter, the biotech industry raised almost $10 billion in financings and partnering, according to Burrill & Co.'s Quarterly Biotechnology Report, which tracks the ongoing performance of the biotechnology industry.   

Biotech stocks surged Friday to 52-week highs, with several major players up on the day, led by Vertex Pharmaceuticals Inc., which jumped on a positive initiation of analyst coverage.   

Genentech Inc. said Wednesday that the U.S. Patent Office rejected one of its key antibody development patents, putting substantial future license revenue at risk.   

The headquarters for stem cell research may not be headed here, but San Diego is still positioned to play a major role in the development of the new technology. And the local legal community is preparing to play its part.   

From the outside, it looks like any other government vehicle.   

Above all else, John Bauhs credits a drug for helping him stop drinking -- a story line some alcoholics, doctors and drug companies hope will become more common as new treatment options emerge.   

Millions of people with diabetes may have an alternative to some or all of their daily needles if the government adopts an advisory panel's recommendation to approve the first insulin that can be inhaled.   

A comprehensive bill that would overhaul U.S. patent law has ignited the passions of many, from the individual inventor to big corporations.   

They're being bred now by the millions, the mutants, created to carry the ghastliest of diseases for the benefit of the human race.